Back to catalogue
№ 045 22 filings · 2021-09-30 → 2026-06-23

AVACTA GROUP PLC

AVCT
Health Care Share price 68.20p Market cap £320m Overall fit 140 /1000

Poor fit for the investor strategy: no operating leverage (pre-revenue), only tangential AI exposure (Tempus AI patient selection), and weak downside protection (cash runway 9 months, convertible bond overhang, dilution history). Valuation is roughly fair but binary and cannot be underwritten with discipline.

Fair value range 40p–90p Mid case · £305m
Absolute upside -4.6% vs current market cap
Conviction 2/5 confidence in fair call
Supports the call
  • Clinical validation of pre|CISION platform with reproducible early efficacy signals
  • Second asset entering clinic Q1 2026 provides multiple upcoming catalysts
  • Balance sheet position and dilution history are well disclosed
Limits the call
  • Binary clinical outcomes with no revenue anchor for valuation
  • Further equity raise almost certain before Q3 2026, quantum unknown
Methodology

Risk-adjusted sum-of-parts platform option value

In one line · bull case

Clinically validated tumour-targeting peptide-drug-conjugate platform with multiple 2026 catalysts and active partnering conversations that could re-rate the equity meaningfully.

In one line · biggest risk

Only 9 months of cash runway against a convertible bond overhang and a share count that has already grown ~70% since mid-2023 — further material dilution is almost certain before valuation resolves.

Drivers
AI beneficiary 22 /100
Only a Tempus AI collaboration for tumor indication selection; not a value chain beneficiary of AI infrastructure spend.
Operating leverage 15 /100
Pre-revenue clinical biotech; the concept does not usefully apply at current scale.
Earnings vs expectations 40 /100
Not enough recurring earnings history to judge; clinical milestones slipped but tolerability data has met/beaten early expectations — call it 40.
Growth momentum 30 /100
Revenue trajectory is flat-to-negative (diagnostics divested); pipeline momentum is real but not yet monetised.
Moat 45 /100
Proprietary FAP-cleaved PDC chemistry and growing IP estate provide some structural advantage, but platform value is unproven at Phase 2/3.
Earnings quality 30 /100
Large non-cash charges (bond derivative revaluation, share-based payments); operating cash burn is the truer signal.
Management quality 35 /100
New CEO/CFO teams appear technically strong, but repeated financing stress, guidance slippage, and 22.75% AGM dissent limit confidence.
Cyclicality 15 /100
Drug pipeline value is largely uncorrelated with macro cycles; funding availability is cyclical but the operating asset is not.
Leverage 55 /100
£23m convertible bond deferred to Oct 2027 plus lease liabilities against £17m cash; not distressed but stretched.
Value-trap signals · 5
  • Repeated dilutive equity raises at falling share prices
  • Multiple convertible bond renegotiations 2024-2025
  • Divestment of prior revenue-generating diagnostics division to fund R&D
  • Cash runway management by asset sale rather than commercial traction
  • 22.75% shareholder vote against remuneration resolution at July 2025 AGM

Avacta Group PLC (AVCT) — Investment Research Note

Executive summary

Avacta is an AIM-listed clinical-stage biopharmaceutical company (post-divestment of its diagnostics operations in 2025) developing the pre|CISION® platform — peptide drug conjugates activated in the tumour microenvironment by fibroblast activation protein (FAP) — with lead asset faridoxorubicin (AVA6000) in Phase 1b and FAP-Exd (AVA6103) entering the clinic in Q1 2026. Operating trajectory across the period covered is a shrinking, cash-burning pure R&D story: revenue near zero, continuing-operations losses of £29m (FY24) and £16m (H1 25), a series of dilutive placings and share-settled convertible bond amortisations that took share count from ~275m (mid-2023) to ~469m today, and cash of £16.9m at Dec 2025 giving only a runway into Q3 2026 2026-01 trading update; 2025-09 H1 25. The single most important valuation point today: this is a pre-revenue, binary-outcome clinical biotech with no visible near-term partnering deal and a still-live convertible bond overhang (£22.95m par, reset conversion price 75p) — the £319m market cap already prices in meaningful platform optionality.

Fair value estimate

  • Fair value range: 40p – 90p per share (implied market cap £188m – £422m).
  • Methodology: risk-adjusted sum-of-parts / platform-option value. There is no earnings, no revenue growth, and no cash flow to discount. I anchor to (i) an estimated £150–200m risk-adjusted NPV for AVA6000 in orphan salivary gland cancer (partnered basis, ~10–15% probability of approval, modest peak sales) plus (ii) £50–150m for AVA6103 platform/pipeline optionality, less (iii) ~£23m convertible bond, plus (iv) £17m cash minus one further equity raise of ~£25m expected before Q3 2026 (which would push share count towards ~500m+ at present prices). Wide range reflects the binary nature of clinical outcomes.
  • Comparison to £319.5m current mcap: mid-point £305m ≈ current. On a per-share basis the mid-point (~65p) is essentially in line with the 68.2p share price.
  • Absolute upside/downside: −34% to +32% on the range, with central case flat. View: fair, with skew to overvalued given financing overhang.

Sector context

  • ICB Health Care classification is correct, but Avacta is more precisely categorised as a clinical-stage biopharma / oncology drug developer — very different in risk profile from healthcare services or medtech peers.
  • Quality/growth/leverage profile is below typical listed health-care peers: no earnings, no meaningful revenue, going-concern-adjacent funding profile, high dilution history.
  • Comparable listed peers: Bicycle Therapeutics (BCYC), Nuvation Bio (NUVB) among peptide/tumour-targeted oncology names; Redx Pharma (REDX) among UK small-cap clinical biotechs. All share the binary clinical-outcome / cash-runway risk profile.

Investment thesis (three bullets)

  • Clinically validated tumour-targeting platform with genuine differentiation. Phase 1b salivary gland cancer cohort showed a 90% disease control rate at last update, with pre|CISION® demonstrated to concentrate doxorubicin in tumour and reduce cardiac toxicity vs standard doxorubicin (12.3% LVEF dysfunction vs 48.4%) 2026-01 trading update; 2024-09 H1 24.
  • Second clinical asset (FAP-Exd, AVA6103) about to enter the clinic in Q1 2026, with a Tempus AI collaboration used to pre-select four responder tumour types (pancreatic, gastric, SCLC, cervical) — a genuine platform expansion event and one of the few concrete AI-tie points in the filings 2026-01 trading update.
  • Active partnering conversations disclosed for both lead assets, with management explicitly stating faridoxorubicin further development is contingent on securing a partner — a partnering deal would materially re-rate the equity and reduce funding risk 2026-01 trading update; 2025-09 H1 25.

Key risks (three bullets)

  • Financing overhang and dilution risk. Cash runway only into Q3 2026 on £16.9m cash; convertible bond £22.95m still outstanding (deferred payments only to Oct 2027, conversion price reset to 75p); share count has already grown from ~275m (mid-2023) to ~469m (Nov 2025) 2026-01 trading update; 2025-11 placing completion; 2025-09 H1 25.
  • Binary clinical outcomes with no revenue offset. Continuing-operations revenue was £56k in H1 25 vs £14m of operating loss; failure of the Phase 1b readouts (SGC survival, TNBC in H1 26) or the FAP-Exd Phase 1a (H2 26) would remove most of the platform value 2025-09 H1 25.
  • Governance/execution concerns. 22.75% of votes against Resolution 2 at the July 2025 AGM signals meaningful shareholder discontent; prior CEO replaced May 2024; convertible bond has required successive renegotiations — pattern of stress and shareholder pushback 2025-07 AGM result; 2024-04 full-year results.

Operating leverage

Not a meaningful concept for Avacta at current scale — this is a pre-revenue R&D company where cost is almost entirely fixed (research £14.3m FY24, SG&A £12.0m FY24, largely people and clinical trial costs) and there is no incremental revenue to leverage. A 10–20% "revenue beat" is not the correct framing; the equivalent question is whether the company can convert the pre|CISION® platform into a partnering deal with an upfront payment and milestones. A single mid-sized global-pharma partnership on faridoxorubicin could reasonably deliver $30–100m upfront plus milestones — that is where the real "leverage" sits, and it depends entirely on clinical readouts. There is no gross-margin trajectory, no capacity utilisation story, and no SaaS-style scale economics to discuss. 2025-09 H1 25 P&L

Value-trap signals

  • Repeated equity raises at progressively lower share prices — £31m at 50p in March 2024, £6.5m in mid-2025, further placing at 50p in Sept 2025, another £22.5m raised in 2025 in total.
  • Successive convertible bond renegotiations (April 2024 reset, August 2025 deferral, October 2025 amendments) — signals ongoing balance-sheet pressure.
  • Runway management by asset sale (Launch Diagnostics, Coris Diagnostics divested in 2025) — the diagnostics division that was pitched as a revenue-generating cash pillar in 2022–2024 has been sold to fund therapeutics R&D, undoing the previous "balanced business model" thesis.
  • Wide gap between guidance rhetoric and cash reality: management refers to a "transformative period" while cash covers only ~9 months of spend.
  • Shareholder pushback: 22.75% against remuneration/authority resolution at July 2025 AGM.

Earnings vs. expectations

This is not a company that meaningfully guides revenue or EPS or is subject to analyst consensus in the conventional sense — the filings are structured around clinical milestones and cash runway rather than P&L outcomes. Where guidance has been set, delivery has been mixed: management guided in 2023 to Phase 2 start in soft-tissue sarcoma in 2024, but by 2025 the pivotal Phase 2 had been reframed into further Phase 1b expansion cohorts and made contingent on partnering. Cash runway guidance has slipped repeatedly (each raise pitches "24 months of runway" that resolves into a shorter period requiring another raise). On the clinical side, AVA6000 has broadly met/beaten early tolerability and preliminary efficacy expectations (a genuine positive), but strategic/commercial milestones (partnering, Phase 2 initiation, NASDAQ dual listing floated in 2024) have consistently slipped.

Conviction

Conviction: 2 (low). Anchoring factors: the business model is unambiguously a binary clinical biotech, and the wide fair-value range is appropriate rather than precise. Limiting factors: (i) the value of pre|CISION® is heavily dependent on Phase 1b/2 readouts still to come and on securing a partner, neither of which can be reliably probability-weighted from filings alone; (ii) further dilution is highly likely before valuation resolves, and the exact quantum is unknowable; (iii) there is no cash-flow-based valuation possible.

Filings consulted · 24

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-06-23Result OF Agm2026-06-23_9630710_result-of-agm.md0.30
  2. 2026-05-29Posting OF Annual Report And Notice OF Agm2026-05-29_9590924_posting-of-annual-report-and-notice-of-agm.md0.95
  3. 2026-01-20Year End Trading Update2026-01-20_9367834_year-end-trading-update.md0.72
  4. 2025-11-03Completion OF Placing And Tvr2025-11-03_9208439_completion-of-placing-and-tvr.md0.59
  5. 2025-10-23Notice OF Investor Presentation2025-10-23_9190790_notice-of-investor-presentation.md0.59
  6. 2025-09-30Interim Half Year Results 20252025-09-30_9138746_interim-half-year-results-2025.md0.77
  7. 2025-09-15Notice OF Interim Results2025-09-15_9106990_notice-of-interim-results.md0.77
  8. 2025-07-02Result OF Agm2025-07-02_8960814_result-of-agm.md0.20
  9. 2025-06-09Posting OF Annual Report And Revised Notice OF Agm2025-06-09_8920282_posting-of-annual-report-and-revised-notice-of-agm.md0.62
  10. 2025-03-31Avacta Quarterly Update2025-03-31_8804153_avacta-quarterly-update.md0.55
  11. 2024-09-30Interim Results2024-09-30_8448144_interim-results.md0.58
  12. 2024-06-26Result OF Agm2024-06-26_8280211_result-of-agm.md0.14
  13. 2024-05-31Posting OF Annual Report And Notice OF Agm2024-05-31_8233243_posting-of-annual-report-and-notice-of-agm.md0.43
  14. 2024-04-30Full Year Results2024-04-30_8163417_full-year-results.md0.45
  15. 2024-02-29Result OF Placing2024-02-29_8062234_result-of-placing.md0.32
  16. 2023-09-28Interim Results For The Period Ending 30 June 20232023-09-28_7782624_interim-results-for-the-period-ending-30-june-2023.md0.41
  17. 2023-06-02Posting OF Annual Report And Notice OF Agm2023-06-02_7556382_posting-of-annual-report-and-notice-of-agm.md0.24
  18. 2023-04-03Notice OF Results And Investor Presentation2023-04-03_7424293_notice-of-results-and-investor-presentation.md0.17
  19. 2022-10-18Result OF Placing2022-10-18_7382449_result-of-placing.md0.17
  20. 2022-10-18Proposed Acquisition OF Launch Diagnostics2022-10-18_7352192_proposed-acquisition-of-launch-diagnostics.md0.19
  21. 2022-09-29Interim Results For The Period Ended 30 June 20222022-09-29_7168995_interim-results-for-the-period-ended-30-june-2022.md0.23
  22. 2022-05-31Posting OF Annual Report And Notice OF Agm2022-05-31_7074624_posting-of-annual-report-and-notice-of-agm.md0.24
  23. 2022-03-30Notice OF Results And Investor Presentation2022-03-30_7093986_notice-of-results-and-investor-presentation.md0.17
  24. 2021-09-30Interim Results For The Period Ended 30 June 20212021-09-30_6598819_interim-results-for-the-period-ended-30-june-2021.md0.23

This research note was authored by a large language model after reading 22 regulatory filings published between 2021-09-30 and 2026-06-23. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.